New vaccine aims to protect african children from deadly salmonella
NCT ID NCT06213506
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new vaccine (iNTS-GMMA) designed to prevent severe Salmonella infections caused by two common strains. Researchers are giving the vaccine to healthy adults, children, and infants in Ghana to check if it is safe and triggers a strong immune response. The ultimate goal is to protect young infants, starting from 6 weeks of age, who are most at risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iNTS-GMMA vaccine (a vaccine against invasive nontyphoidal Salmonella)
- What this could lead to
- If successful, this could lead to a vaccine that protects African infants and children from severe, often deadly Salmonella infections.
- What could go wrong
- This is an early Phase 2 trial with only 215 participants, so the vaccine may not prove safe or effective enough for wider use. Side effects like pain, fever, or allergic reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALMONELLA INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Kumasi, Ghana
More trials for these conditions
Other studies related to the condition(s) this trial covers.